TScan Therapeutics, Inc.TCRXEarnings & Financial Report

Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)

Deep AnalysisCompare

TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel T cell receptor (TCR) immunotherapies for hard-to-treat cancers. Its proprietary platform identifies high-affinity naturally occurring TCRs targeting tumor antigens, with pipeline candidates spanning hematological malignancies and solid tumors, operating in the global oncology therapeutics market.